Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

First Ophthalmic Formulation Of Bevacizumab Among New Filings At EMA

Executive Summary

Using the cancer drug off-label to treat wet AMD has been controversial.

You may also be interested in...



Bluebird’s Eli-Cel Gene Therapy Among Myriad New Drugs Seeking EU Approval

An advanced immunotherapy for recurrent glioblastoma and the first biosimilar version of Lucentis for age-related macular degeneration have also been submitted for review by the European Medicines Agency for potential pan-EU authorization.

Seeing Is Believing: New Approaches For Treating Eye Disorders

Developers of new ophthalmic products are thinking outside of the box. A raft of new gene therapies are progressing in the clinic, including a gene therapy paired with biomimetic goggles. Elsewhere, technology players are partnering with traditional biopharmaceutical companies and bringing algorithms, machine learning and microelectronics to bear on eye disorders and disease diagnostics.

EMA’s CHMP Is Set To Adopt Position On Another Avastin Biosimilar

The market for biosimilar Avastin is set to form imminently, with two players holding final approvals from the European Commission waiting in the wings. In the coming days, the EMA’s Committee for Medicinal Products for Human Use is likely to issue an opinion on a further application.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS142367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel